MA28883B1 - Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl) amino]phenoxy}-n-methylpyridine-2-carboxamide - Google Patents

Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl) amino]phenoxy}-n-methylpyridine-2-carboxamide

Info

Publication number
MA28883B1
MA28883B1 MA29788A MA29788A MA28883B1 MA 28883 B1 MA28883 B1 MA 28883B1 MA 29788 A MA29788 A MA 29788A MA 29788 A MA29788 A MA 29788A MA 28883 B1 MA28883 B1 MA 28883B1
Authority
MA
Morocco
Prior art keywords
amino
methylpyridine
carboxamide
phenoxy
trifluoromethyl
Prior art date
Application number
MA29788A
Other languages
English (en)
Inventor
Michael Loegers
Reinhold Gehring
Oliver Kuhn
Mike Matthaeus
Klaus Mohrs
Matthias Mueller-Gliemann
Juergen Stiehl
Mathias Berwe
Jana Lenz
Werner Heilmann
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28883(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of MA28883B1 publication Critical patent/MA28883B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
MA29788A 2004-09-29 2007-03-30 Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl) amino]phenoxy}-n-methylpyridine-2-carboxamide MA28883B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04023131 2004-09-29

Publications (1)

Publication Number Publication Date
MA28883B1 true MA28883B1 (fr) 2007-09-03

Family

ID=35457568

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29788A MA28883B1 (fr) 2004-09-29 2007-03-30 Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl) amino]phenoxy}-n-methylpyridine-2-carboxamide

Country Status (35)

Country Link
US (1) US8124782B2 (fr)
EP (1) EP1797037B1 (fr)
JP (2) JP2008514657A (fr)
KR (1) KR101263032B1 (fr)
CN (1) CN101052619B (fr)
AR (1) AR053973A1 (fr)
AU (1) AU2005289099B2 (fr)
BR (1) BRPI0515944B1 (fr)
CA (1) CA2581835C (fr)
CU (1) CU23754B7 (fr)
CY (1) CY1116126T1 (fr)
DK (1) DK1797037T3 (fr)
DO (1) DOP2005000183A (fr)
EC (1) ECSP077357A (fr)
ES (1) ES2532377T3 (fr)
GT (1) GT200500269A (fr)
HK (1) HK1113484A1 (fr)
HN (1) HN2005000768A (fr)
HR (1) HRP20150295T1 (fr)
IL (1) IL182046A0 (fr)
MA (1) MA28883B1 (fr)
MY (1) MY149873A (fr)
NO (1) NO339647B1 (fr)
NZ (1) NZ554119A (fr)
PE (5) PE20091586A1 (fr)
PL (1) PL1797037T3 (fr)
PT (1) PT1797037E (fr)
SG (1) SG155997A1 (fr)
SI (1) SI1797037T1 (fr)
SV (1) SV2006002243A (fr)
TW (1) TWI382973B (fr)
UA (1) UA90691C2 (fr)
UY (1) UY29143A1 (fr)
WO (1) WO2006034796A1 (fr)
ZA (1) ZA200702511B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2359244C (fr) 1999-01-13 2013-10-08 Bayer Corporation Diphenyle urees a substitution .omega.-carboxy aryle en tant qu'inhibiteurs de la kinase p38
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
PT1626714E (pt) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
ES2297490T3 (es) 2003-07-23 2008-05-01 Bayer Pharmaceuticals Corporation Omega-carboxiarildifenilurea fluoro sustituida para el tratamiento y prevencion de enfermadades y afecciones.
BRPI0515946A (pt) * 2004-09-29 2008-08-12 Bayer Healthcare Ag sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo
WO2006034796A1 (fr) 2004-09-29 2006-04-06 Bayer Healthcare Ag Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide
JP5304241B2 (ja) 2005-03-07 2013-10-02 バイエル・ヘルスケア・エルエルシー 癌の処置用のオメガ−カルボキシアリール置換ジフェニルウレアを含む医薬組成物
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
JP2010509382A (ja) * 2006-11-14 2010-03-25 バイエル・シェーリング・ファルマ・アクチェンゲゼルシャフト ４−［４−（｛［４−クロロ−３−（トリフルオロメチル）フェニル］カルバモイル｝アミノ）−３−フルオロフェノキシ］−ｎ−メチルピリジン−２−カルボキサミドの多形ｉｉ
EP2195286A2 (fr) 2007-09-10 2010-06-16 Cipla Limited Procédé de préparation d'un inhibiteur de la kinase raf et intermédiaires utilisables dans ledit procédé
WO2009054004A2 (fr) * 2007-10-22 2009-04-30 Natco Pharma Limited Nouveau procédé pour la préparation du sorafénib
US8217061B2 (en) 2008-01-17 2012-07-10 Sicor Inc. Polymorphs of sorafenib tosylate and sorafenib hemi-tosylate, and processes for preparation thereof
US20090253913A1 (en) * 2008-03-06 2009-10-08 Pierluigi Rossetto Process for the preparation of sorafenib and salts thereof
CN103254126A (zh) * 2008-09-19 2013-08-21 苏州泽璟生物制药有限公司 氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
CA2775296A1 (fr) 2009-09-24 2011-03-31 Ranbaxy Laboratories Limited Polymorphes de sels d'addition acide de sorafenib
US8609854B2 (en) * 2009-09-24 2013-12-17 Ranbaxy Laboratories Limited Process for the preparation of sorafenib tosylate
WO2011058522A1 (fr) 2009-11-12 2011-05-19 Ranbaxy Laboratories Limited Sel d'ethylsulfonate de sorafenib et son procede de preparation
WO2011076711A2 (fr) 2009-12-23 2011-06-30 Ratiopharm Gmbh Polymorphes de 4-[4-[[4-chloro-3-(trifluorométhyl)phényl]carbamoylamino]phénoxy]-n-méthylpyridine-2-carboxamide
CA2788146C (fr) 2010-01-29 2014-11-25 Ranbaxy Laboratories Limited Solvate de dimethylsulfoxyde de sorafenib
CN102190616B (zh) * 2010-03-18 2015-07-29 苏州泽璟生物制药有限公司 一种氘代的ω-二苯基脲的合成及生产的方法和工艺
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CN102617458A (zh) * 2010-05-18 2012-08-01 张南 抗癌用化合物的制备方法
US20130183268A1 (en) 2010-07-19 2013-07-18 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
MX2013003695A (es) 2010-10-01 2013-05-20 Bayer Ip Gmbh Combinaciones que contienen n-(2-arilamino) arilsulfonamida sustituida.
WO2012071425A1 (fr) 2010-11-22 2012-05-31 Teva Pharmaceutical Industries Ltd. Formes à l'état solide de bésylate de sorafénib et procédés de préparation
EP2559431A1 (fr) 2011-08-17 2013-02-20 Ratiopharm GmbH Composition pharmaceutique comportant du 4-[4-[[4-Chloro-3-(trifluoromethyl)phényl]carbamoylamino]phénoxy]-N-méthyl-pyridine-2-carboxamide
CN103664771B (zh) * 2012-09-19 2016-03-30 齐鲁制药有限公司 索拉非尼的晶型a及其制备方法
WO2014118807A1 (fr) * 2013-02-04 2014-08-07 Intas Pharmaceuticals Limited Nouveau procédé de préparation de tosylate de sorafénib de forme iii
CN104710354A (zh) * 2013-12-13 2015-06-17 江苏豪森药业股份有限公司 高纯度索拉非尼的制备方法
CN104761492A (zh) * 2014-01-03 2015-07-08 正大天晴药业集团股份有限公司 对甲苯磺酸索拉非尼的晶型及其制备方法
CN104177292A (zh) * 2014-08-08 2014-12-03 亿腾药业（泰州）有限公司 一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法
CN105439947A (zh) * 2014-12-01 2016-03-30 石药集团中奇制药技术（石家庄）有限公司 一种甲苯磺酸索拉非尼新晶型及其制备方法
EP3109236B1 (fr) 2015-06-23 2017-08-09 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Procédé évolutif pour la préparation de solvate d'éthanol tosylate de sorafénibe et tosylate de sorafénibe forme iii
CN105181844A (zh) * 2015-09-11 2015-12-23 江苏嘉逸医药有限公司 一种高效液相色谱法测定甲苯磺酸索拉非尼含量和有关物质的方法
CN105585523A (zh) * 2015-12-29 2016-05-18 上海北卡医药技术有限公司 一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途
CN107840823B (zh) * 2016-09-20 2021-08-17 意大利合成制造有限公司 用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
CN107915676A (zh) * 2017-10-26 2018-04-17 魏海霞 索拉非尼的制备方法
CN109796400B (zh) * 2017-11-16 2022-07-29 四川科伦药物研究院有限公司 一种甲苯磺酸索拉菲尼晶型及其制备方法
CN113773249A (zh) * 2020-06-10 2021-12-10 杭州中美华东制药有限公司 索拉非尼游离碱晶型Form X及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU86960A1 (fr) * 1987-07-31 1989-03-08 Oreal Procede de preparation de piperidino-6 diamino-2,4 pyrimidine oxyde-3 et composes nouveaux
JPH02934A (ja) * 1988-05-27 1990-01-05 Konica Corp 非線形光学材料
JP2971291B2 (ja) * 1993-06-02 1999-11-02 田辺製薬株式会社 光学活性２−アミノ酪酸の製法
JP3866323B2 (ja) * 1996-03-27 2007-01-10 ポーラ化成工業株式会社 新規ｎ−ベンジルベンズアミド誘導体
JPH09316069A (ja) * 1996-03-28 1997-12-09 Ajinomoto Co Inc 新規キサントン誘導体
EP1140840B1 (fr) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
GT200000002AA (es) * 1999-01-13 2007-06-15 Ureas difenilicias x-carboxiaril sustituidas como inhibidores de raf quinasa
GB2367816A (en) * 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
ES2275931T5 (es) * 2001-12-03 2018-10-23 Bayer Healthcare Llc Compuestos de aril-urea en combinación con otros agentes citostáticos o citotóxicos para tratamiento de cánceres humanos
US20030207872A1 (en) 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE10203086A1 (de) * 2002-01-28 2003-07-31 Bayer Ag 5-Ring Heterozyklen
DK1478358T3 (da) * 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
EP1842852A1 (fr) * 2002-08-13 2007-10-10 Sandoz AG Un intermediaire de cefdinir
PT1559715E (pt) * 2002-10-21 2007-10-24 Kirin Pharma Kk Formas cristalinas de sais de n-[2-cloro-4-[6, 7-dimetoxi-4-quinolil)oxi]finil]-n'-(5-metil-3-isoxazolil) ureia
PT1626714E (pt) 2003-05-20 2007-08-24 Bayer Pharmaceuticals Corp Diarilureias para doenças mediadas por pdgfr
WO2006034796A1 (fr) 2004-09-29 2006-04-06 Bayer Healthcare Ag Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n-methylpyridine-2-carboxamide

Also Published As

Publication number Publication date
NO20072173L (no) 2007-06-14
EP1797037B1 (fr) 2014-12-17
UA90691C2 (en) 2010-05-25
CU23754B7 (es) 2012-01-31
ECSP077357A (es) 2007-04-26
PL1797037T3 (pl) 2015-07-31
SI1797037T1 (sl) 2015-06-30
PE20060825A1 (es) 2006-10-20
CN101052619B (zh) 2012-02-22
CU20070069A7 (es) 2010-11-27
EP1797037A1 (fr) 2007-06-20
DOP2005000183A (es) 2006-03-31
JP5583190B2 (ja) 2014-09-03
ES2532377T3 (es) 2015-03-26
TW200626551A (en) 2006-08-01
PT1797037E (pt) 2015-03-17
JP2008514657A (ja) 2008-05-08
PE20091584A1 (es) 2009-10-28
NO339647B1 (no) 2017-01-16
UY29143A1 (es) 2006-04-28
HK1113484A1 (en) 2008-10-03
BRPI0515944B1 (pt) 2021-11-09
NZ554119A (en) 2010-07-30
CN101052619A (zh) 2007-10-10
WO2006034796A1 (fr) 2006-04-06
PE20091587A1 (es) 2009-11-05
SG155997A1 (en) 2009-10-29
PE20091586A1 (es) 2009-10-31
AR053973A1 (es) 2007-05-30
SV2006002243A (es) 2006-10-13
KR20070058676A (ko) 2007-06-08
BRPI0515944A (pt) 2008-08-12
MY149873A (en) 2013-10-31
CY1116126T1 (el) 2017-02-08
HRP20150295T1 (hr) 2015-05-22
ZA200702511B (en) 2008-07-30
US8124782B2 (en) 2012-02-28
PE20091585A1 (es) 2009-10-31
KR101263032B1 (ko) 2013-05-09
DK1797037T3 (en) 2015-03-30
IL182046A0 (en) 2007-07-24
US20080262236A1 (en) 2008-10-23
AU2005289099A1 (en) 2006-04-06
GT200500269A (es) 2006-05-11
CA2581835A1 (fr) 2006-04-06
TWI382973B (zh) 2013-01-21
AU2005289099B2 (en) 2012-07-19
JP2013067625A (ja) 2013-04-18
HN2005000768A (es) 2010-09-17
CA2581835C (fr) 2012-12-18

Similar Documents

Publication Publication Date Title
MA28883B1 (fr) Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl) amino]phenoxy}-n-methylpyridine-2-carboxamide
UA91520C2 (en) Thermodynamically stable form of tosylate
IL253119A0 (en) 4-{4[({[4-chloro-3-(trifluoroacetyl)phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate and preparations including it
PL2097381T3 (pl) Jednowodzian 4-[4-({[4-chloro-3-(trifluorometylo)fenylo)]karbamoilo}amino)-3-fluorofenoksy]-N-metylopirydyno-2-karboksyamidu
IL182095A0 (en) Process for making phenoxy benzamide compounds
IL175933A (en) Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt, a pharmaceutical composition comprising the same and a process for preparing the same
ZA201101891B (en) The salts of n-[4-(1-cyanocyclopentyl)phenyl]-2-(4-pyridyl methyl)amino-3-pyridinecarboxamide
IL192241A (en) A process for making 4 - (benzimidazolylmethylamino) - benzamides and their salts
ATE467995T1 (de) Verfahren und system für medienunabhängiges handover unter verwendung des oamp-protokolls
EP2007213A4 (fr) Procédé permettant de préparer une protéine de lactosérum modifiée et déshydratée
FR2877828B1 (fr) Machine et procede lave-vaisselle
IL182996A0 (en) Process for preparing quinoline compounds and products obtained therefrom
FI20031904A0 (fi) Menetelmä lignoselluloosatuotteen muokkaamiseksi
IL172169A0 (en) Processes for preparing (2s) - 3 - (4 - {2 - [amino] - 2 - oxoethoxy}
FR2876998B1 (fr) Procede de preparation de gamma-liv205
MA29005B1 (fr) Nouveaux procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
DE602005009239D1 (de) Verfahren zur holzverarbeitung
NO20044183L (no) Fremgangsmate for skjaering av ost
DE50204325D1 (de) Verfahren zur spaltung des methyl 4-(2-chlor-4-fluorphenyl)-2-(3,5-difluor-2-pyridinyl)-6-methyl-1,4-dihydro-5-pyrimidincarboxylat-racemats
IL182445A0 (en) Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4difluoromethoxy-8-methanesulfona mido-dibenzo[b,d]furan-1-caboxamide
EP1943820A4 (fr) Terminal, procede et produit-programme informatique pour l'enregistrement de contenu de diffusion
CL2007001691A1 (es) Metodo para hacer n-hidroxi-3-(4(((2-(2-metil-1h-indol-3-il)etil)amino)metil)fenil)-2e-2-propenamida.
TWI320407B (en) Method for preparing n-(trifluoromethyl substituted phenyl) maleimides
FR2890531B1 (fr) Procede de fabrication ou de pre-assemblage d'un filet, notamment un filet de peche, filet de peche ainsi obtenu
FR2881319B3 (fr) Procede de fabrication ou de pre-assemblage d'un filet, notamment un filet de peche, filet de peche ainsi obtenu